Earn 3 CPD Points onlinE premix insulin and dpp-4 inhibitors new Sit2Mix trial provides first global evidence An important trial using a premix insulin (BIAsp 30) as the initial insulin in type 2 diabetes patients uncontrolled on oral agents provides evid

Abstract

• In selected type 2 diabetes patients, biphasic insulin aspart 30 (BIAsp 30) can be safely combined with DPP-4 inhibitors and metformin to lower blood glucose levels • This combination offers benefits for patients who can accommodate a daily routine of at least two main meals and are willing to administer injections subcutaneously • Using either once-or twice-daily BIAsp 30 with a DPP-4 inhibitor and metformin allows more patients to reach target HbA 1c levels (<7%) without hypoglycaemic events • These findings are relevant and important for type 2 diabetes patients for whom pre-mix insulin has been selected by the clinician as the starting insulin of choice • The addition of these evidence-supported regimens as intensification therapy adds to the clinician's armamentarium when considering different approaches for individual patients. The three regimens (BIAsp 30 BID + sitagliptin, BIAsp 30 QD + sitagliptin, BIAsp 30 BID replacing sitagliptin) are not burdensome; neither are compliance and convenience compromised • This trial provides, for the first time, clear evidence that the combination of BIAsp 30 + sitagliptin is efficacious and well tolerated